Abivax stock price target raised to $114 from $95 at JMP Securities

Published 25/09/2025, 10:54
Abivax stock price target raised to $114 from $95 at JMP Securities

Investing.com - JMP Securities has raised its price target on Abivax (NASDAQ:ABVX) to $114.00 from $95.00 while maintaining a Market Outperform rating on the stock. The new target aligns with the broader analyst consensus, as tracked by InvestingPro, which shows targets ranging from $95 to $116, suggesting further upside potential from the current trading price of $82.55.

The firm expects Abivax to present additional analyses of its drug obefazimod, including its efficacy in advanced treatment, advanced treatment-naïve patients, refractory, and JAK-inhibitor failed patients.

JMP believes these results could serve as a differentiating feature for obefazimod, highlighting its effectiveness in the most severe ulcerative colitis patient population.

The price target increase reflects JMP’s updated model incorporating Abivax’s first-half 2025 financial results and the July equity financing, as well as an increased peak penetration rate from 20% to 22%, which raises U.S. peak sales estimates in ulcerative colitis from $2.6 billion to $2.9 billion.

Following the equity financing, JMP estimates Abivax has a pro forma cash position of approximately $800 million, which it believes will support operations into the fourth quarter of 2027.

In other recent news, Abivax SA has announced the launch of a $400 million public offering of American Depositary Shares, which aims to expand its financial capabilities. This move comes alongside Piper Sandler’s decision to raise Abivax’s stock price target to $112, citing promising Phase 3 data for obefazimod in treating ulcerative colitis. The firm has adjusted its financial models to reflect a significant revenue potential in early-line UC treatment, projecting €2,656 million in US revenue by 2035. Additionally, Guggenheim has maintained a Buy rating on Abivax, supported by promising data from Phase IIb readouts for competing inflammatory bowel disease treatments.

Meanwhile, Abivax is set to present its Phase 3 data on obefazimod at the United European Gastroenterology Congress next month. On a related note, JMP Securities has reiterated its Market Outperform rating for Rapport Therapeutics, maintaining a price target of $77. The research firm remains optimistic about Rapport’s prospects following strong clinical trial results. These recent developments highlight the ongoing activities and analyst perspectives surrounding Abivax and Rapport Therapeutics .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.